cell-based meat
-
DATABASE (857)
-
ARTICLES (608)
Co-founder, CTO of Meatable
Daan Luining is the Dutch co-founder and CTO at cell-based meat startup Meatable, the first to claim a highly scalable culture technology, where he has worked since 2018. He is also a research director at the Cellular Agriculture Society in Leiden, a joint initiative for cell-based startups to share knowledge and to collaborate on projects to further scale the sector. Luining is also on the board of directors at the not-for-profit Cultured Meat Foundation that promotes sector innovation. His past posts have all been in the area of research, either as a researcher or a technician, and at the same time as completing studies. His last job was as a research strategist at New York-based New Harvest, a callular food rsearch funding body, where he worked for a year and met Dr. Kotter, the inventor of Meatable’s cellular technology. His research positions from 2009–15 were in the area of cell culture, mass spectrometry and DNA sequencing at the Maastricht University, University Medical Center Amsterdam, Utrecht University and Leiden University. Luining holds a master’s in biological sciences from Leiden University in the Netherlands.
Daan Luining is the Dutch co-founder and CTO at cell-based meat startup Meatable, the first to claim a highly scalable culture technology, where he has worked since 2018. He is also a research director at the Cellular Agriculture Society in Leiden, a joint initiative for cell-based startups to share knowledge and to collaborate on projects to further scale the sector. Luining is also on the board of directors at the not-for-profit Cultured Meat Foundation that promotes sector innovation. His past posts have all been in the area of research, either as a researcher or a technician, and at the same time as completing studies. His last job was as a research strategist at New York-based New Harvest, a callular food rsearch funding body, where he worked for a year and met Dr. Kotter, the inventor of Meatable’s cellular technology. His research positions from 2009–15 were in the area of cell culture, mass spectrometry and DNA sequencing at the Maastricht University, University Medical Center Amsterdam, Utrecht University and Leiden University. Luining holds a master’s in biological sciences from Leiden University in the Netherlands.
CEO and co-founder of Because Animals
Shannon Falconer graduated with a master’s in botany at the University of Vancouver in 2006. She also completed a PhD in biochemistry at The McMaster University in 2014. She went on to work as a postdoctoral researcher at Stanford University until 2016 when she decided to become the CEO and co-founder of biotech startup Because Animals. She also led the biotech’s R&D team to develop plant-based nutritional cookies and treats for dog and cats. Because Animals now aims to produce the world’s first cell-based cultured meat products for pets.
Shannon Falconer graduated with a master’s in botany at the University of Vancouver in 2006. She also completed a PhD in biochemistry at The McMaster University in 2014. She went on to work as a postdoctoral researcher at Stanford University until 2016 when she decided to become the CEO and co-founder of biotech startup Because Animals. She also led the biotech’s R&D team to develop plant-based nutritional cookies and treats for dog and cats. Because Animals now aims to produce the world’s first cell-based cultured meat products for pets.
Co-founder, CEO of Meatable
Krijn De Nood is the Dutch co-founder and CEO at cell-based meat startup Meatable, the first to claim a highly scalable culture technology with the use of pluripotent stem cells, where he has worked since 2018. He previously worked at McKinsey for six-and-a-half years in Amsterdam, New York and in Kenya. Prior to that, he worked as an equity derivatives trader at derivative trading company All Options after a short stint at Barclays Capital.De Nood holds two first degrees from the University of Amsterdam, in philosophy and in economics and finance.
Krijn De Nood is the Dutch co-founder and CEO at cell-based meat startup Meatable, the first to claim a highly scalable culture technology with the use of pluripotent stem cells, where he has worked since 2018. He previously worked at McKinsey for six-and-a-half years in Amsterdam, New York and in Kenya. Prior to that, he worked as an equity derivatives trader at derivative trading company All Options after a short stint at Barclays Capital.De Nood holds two first degrees from the University of Amsterdam, in philosophy and in economics and finance.
Co-founder of Meatable
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Founded in 2011, London-based Agronomics Limited’s principal investing interest is in environmentally-friendly alternatives to the traditional production of meat, wherever they may be located. There are currently 17 companies in its portfolio, all of them in the cellular-based or plant-based protein category and sustainable food production.Its most recent declared investments have been in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the December 2020 undisclosed pre-seed round of Chinese cellular foodtech CellX.
Founded in 2011, London-based Agronomics Limited’s principal investing interest is in environmentally-friendly alternatives to the traditional production of meat, wherever they may be located. There are currently 17 companies in its portfolio, all of them in the cellular-based or plant-based protein category and sustainable food production.Its most recent declared investments have been in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the December 2020 undisclosed pre-seed round of Chinese cellular foodtech CellX.
Jeffrey Leiden is a physician and scientist of more than 40 years, who is currently the executive chairman of US-based multinational biotech company Vertex Pharmaceuticals. Leiden is also the chairman of Casana, a remote healthcare platform and the chairman of Tmunity, a biotech dedicated to T-cell research. In March 2021, he participated as an angel investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Jeffrey Leiden is a physician and scientist of more than 40 years, who is currently the executive chairman of US-based multinational biotech company Vertex Pharmaceuticals. Leiden is also the chairman of Casana, a remote healthcare platform and the chairman of Tmunity, a biotech dedicated to T-cell research. In March 2021, he participated as an angel investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
The biotech will expand its popular range of organic and probiotic treats for dogs and cats with cell-based pet food, planned for launch in 2022.
The biotech will expand its popular range of organic and probiotic treats for dogs and cats with cell-based pet food, planned for launch in 2022.
New York-based Humboldt Fund invests in startups with the potential to solve critical issues of our time across the areas of food production, healthcare, energy, and construction and manufacturing materials. It currently has 14 companies in its portfolio. Its most recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the February 2021 $16m seed round of US biotech Cellino Biotech.
New York-based Humboldt Fund invests in startups with the potential to solve critical issues of our time across the areas of food production, healthcare, energy, and construction and manufacturing materials. It currently has 14 companies in its portfolio. Its most recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the February 2021 $16m seed round of US biotech Cellino Biotech.
Co-founder, CCO of Cocuus
Patxi Larumbe is the Spanish CCO and co-founder at 3D printing food tech and cell-based meat startup Cocuus, where he has worked since he co-founded it in 2017. Before Cocuus, Larumbe founded and directed eight other companies, the majority, like Cocuus, also based in Pamplona, Navarre. During his extensive entrepreneurial career, Larumbe had experience with design and manufacturing in 3D processes, which he used to innovate in Cocuus. Before Cocuus, he was a director at his building materials distribution company, On Clima, for two years, which was preceded by a two-year stint heading up Tohama, an IoT tech developer for Somfy products. Prior to that, he was commercial director for 20 years at building services company Terradisa and also founded its Catalonia offices.From 2000–2013, Larumbe was the founder and board member at Acustica Arquitectonica, an acoustic architectural design company and from 1995–2005, he had the same responsibilities at his hospitality company, Ostatu Zaharra. Other companies he founded were were Render (1990–96), Netcorp Factory (1996–2000) and No Solo Futbol ("Not Just Soccer") (2000–2004). Larumbe studied electronics at first degree level in Pamplona.
Patxi Larumbe is the Spanish CCO and co-founder at 3D printing food tech and cell-based meat startup Cocuus, where he has worked since he co-founded it in 2017. Before Cocuus, Larumbe founded and directed eight other companies, the majority, like Cocuus, also based in Pamplona, Navarre. During his extensive entrepreneurial career, Larumbe had experience with design and manufacturing in 3D processes, which he used to innovate in Cocuus. Before Cocuus, he was a director at his building materials distribution company, On Clima, for two years, which was preceded by a two-year stint heading up Tohama, an IoT tech developer for Somfy products. Prior to that, he was commercial director for 20 years at building services company Terradisa and also founded its Catalonia offices.From 2000–2013, Larumbe was the founder and board member at Acustica Arquitectonica, an acoustic architectural design company and from 1995–2005, he had the same responsibilities at his hospitality company, Ostatu Zaharra. Other companies he founded were were Render (1990–96), Netcorp Factory (1996–2000) and No Solo Futbol ("Not Just Soccer") (2000–2004). Larumbe studied electronics at first degree level in Pamplona.
Founded in 2016, Berlin-based investor BlueYard invests in startups aiming to tackle the planet’s greatest challenges. It typically makes $1m–3m as an initial investment and has no geographical bias. Its most recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech and in the February 2021 $4m seed round of Next Matter, a German Open Source automation tool for operations teams.
Founded in 2016, Berlin-based investor BlueYard invests in startups aiming to tackle the planet’s greatest challenges. It typically makes $1m–3m as an initial investment and has no geographical bias. Its most recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech and in the February 2021 $4m seed round of Next Matter, a German Open Source automation tool for operations teams.
Co-founder, COO of Cocuus
Daniel Rico Aldaz is the Spanish COO and co-founder at 3D printing food tech and cell-based meat startup Cocuus, where he has worked since he co-founded it in 2017. Before Cocuus, Rico founded an industrial design company, Rico Ingenio, which was established in 2009, where he continues to be a founding partner.His last full-time position before Cocuus was at systems automation company Kaizen for less than a year, where he headed up the technical office. Prior to that, Rico briefly led the computer-to-plate (CTP) and quality control departments at printers Estellaprint. For 15 years, until 2016, Rico was founder at his own industrial design company El Seis Y El Cuatro.Rico’s varied career has also seen him as head designer of children's parks and gyms at Mader Play, as an IT teacher at a worker’s foundation and as both a graphic and an artistic designer in two communication agencies and a lighting company. During his career, Rico has had experience with design and manufacturing in 3D processes, which he used to innovate in Cocuus. Rico did not attend university. He studied music and design at high school.
Daniel Rico Aldaz is the Spanish COO and co-founder at 3D printing food tech and cell-based meat startup Cocuus, where he has worked since he co-founded it in 2017. Before Cocuus, Rico founded an industrial design company, Rico Ingenio, which was established in 2009, where he continues to be a founding partner.His last full-time position before Cocuus was at systems automation company Kaizen for less than a year, where he headed up the technical office. Prior to that, Rico briefly led the computer-to-plate (CTP) and quality control departments at printers Estellaprint. For 15 years, until 2016, Rico was founder at his own industrial design company El Seis Y El Cuatro.Rico’s varied career has also seen him as head designer of children's parks and gyms at Mader Play, as an IT teacher at a worker’s foundation and as both a graphic and an artistic designer in two communication agencies and a lighting company. During his career, Rico has had experience with design and manufacturing in 3D processes, which he used to innovate in Cocuus. Rico did not attend university. He studied music and design at high school.
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
Taavet Hinrikus is the Estonian-born co-founder and CEO of money transfer platform and unicorn TransferWise (now called Wise). He was formerly Skype’s Director of Strategy and is a prolific angel investor across sectors and technologies, with investments in around 30 startups to date. His most recent investments include in the April 2021 $11m Series A round of automatic contract negotiator PACTUM and in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Taavet Hinrikus is the Estonian-born co-founder and CEO of money transfer platform and unicorn TransferWise (now called Wise). He was formerly Skype’s Director of Strategy and is a prolific angel investor across sectors and technologies, with investments in around 30 startups to date. His most recent investments include in the April 2021 $11m Series A round of automatic contract negotiator PACTUM and in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
DSM Venturing is the investment arm of major Dutch biotech company DSM that has been investing in startups since 2006. The company currently has 36 startups in its portfolio across geographies and has managed three exits to date. It typically invests between €100,000 and €5m, with a lifetime investment varying from €1m–20m and usually requires board membership alongside investment. It has offices in the Netherlands and the US, both on the east and west coast. Its recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the same month, in the $8m Series A round of British anti-pollution biotech Deep Branch Biotechnology.
DSM Venturing is the investment arm of major Dutch biotech company DSM that has been investing in startups since 2006. The company currently has 36 startups in its portfolio across geographies and has managed three exits to date. It typically invests between €100,000 and €5m, with a lifetime investment varying from €1m–20m and usually requires board membership alongside investment. It has offices in the Netherlands and the US, both on the east and west coast. Its recent investments include in the March 2021 $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech, and in the same month, in the $8m Series A round of British anti-pollution biotech Deep Branch Biotechnology.
Yali Bio: Recreating a juicy steak in plant-based alternatives
Founded by the former head of Impossible Foods’ pilot plant, this Bay Area genomics and foodtech startup is one of the first to engineer a better fat for plant-based meat
Plant-based eggs (Part II): The foodtech startups to watch
Here’s a shortlist of the foodtech startups to watch in the global vegan egg market
Plant-based eggs: The next big thing in the alternative protein market
Plant-based eggs may be the fastest growing segment in plant-based foods, but hacking the formula for a perfect egg substitute is proving a hurdle. Are alt-protein startups up for the challenge?
New Food Invest: Plant-based cheese, the next investment boom?
With alt-protein startups experiencing a global funding boom, industry experts and investors share their views about emerging trends in diverse food sectors
Do plant-based meat alternatives stand a chance in China, the world's largest meat consumer?
Major food brands and foodtech startups are trying to build their following in a nascent market forecast to grow to nearly $12bn worth by 2023
Future Food Asia 2021: Two winners take home $100,000 each
Agrifood startups, corporations and investors urged to collaborate and take action, tackling challenges in nutrition and climate change
Zhenmeat: Offering a modern plant-based meat alternative in China
The Chinese startup is providing a product adapted for Chinese tastes in an emerging market.
Plant-based meat faces backlash in China despite gaining traction
An innocuous video clip sparked debate on social media over plant-based meat, with suspicion about its nutritional value, cost-effectiveness and even the motives of foreign companies
Indonesia's Green Rebel Foods to take its Asian-inspired plant-based meat regional
F&B veteran duo behind the Burgreens spinoff plans Series A fundraising by end-2021 for manufacturing and regional expansion
New Food Invest: Challenges of growing an alt-protein startup
Founders of three alt-protein startups in the US share what motivated them to start, their personal experiences growing the businesses, getting funding and finding strategic partners
In a nascent market, one-year-old Starfield has brought its offerings to around 3,000 F&B outlets and generated RMB 10m in revenue
TreeFrog Therapeutics: Mimicking how stem cells grow in the human body
The French biotech’s proprietory technology to cultivate pluripotent stem cells in a 3D environment can be scaled to mass-produce high-quality cells to treat diseases such as Parkinson’s
TurtleTree Labs: Creating sustainable mammalian milk alternatives from stem cells
Founder’s search for high-quality dairy milk led to the creation in a lab of naturally occurring ingredients found in human milk for supply to dairy milk and infant formula businesses
eFishery poised to benefit from Indonesia's growing aquaculture sector
eFishery's IoT automatic feeding system is delivering efficiencies and boosting output for small fish farmers, driving strong growth for the aquaculture startup.
SWITCH Singapore: Race in agrifood tech as a solution to feeding 10bn people
While the potential gains are huge, giving tech solutions to farmers, especially smallholders in developing countries, remains a work in progress
Sorry, we couldn’t find any matches for“cell-based meat”.
POPULAR DATABASE
